Current development of mTOR inhibitors as anticancer agents

@article{Faivre2006CurrentDO,
  title={Current development of mTOR inhibitors as anticancer agents},
  author={Sandrine J Faivre and Guido Kroemer and Eric Raymond},
  journal={Nature Reviews Drug Discovery},
  year={2006},
  volume={5},
  pages={671-688}
}
Mammalian target of rapamycin (mTOR) is a kinase that functions as a master switch between catabolic and anabolic metabolism and as such is a target for the design of anticancer agents. The most established mTOR inhibitors — rapamycin and its derivatives — showed long-lasting objective tumour responses in clinical trials, with CCI-779 being a first-in-class mTOR inhibitor that improved the survival of patients with advanced renal cell carcinoma. This heralded the beginning of extensive clinical… Expand

Paper Mentions

Interventional Clinical Trial
The mainstay of chondrosarcoma treatment is a wide surgical resection. Unfortunately, this is a rare occurrence, and patients with incomplete resection have very poor therapeutic… Expand
ConditionsChondrosarcoma
InterventionDrug
Interventional Clinical Trial
Define the maximum tolerated dose and dose limiting side-effects of temsirolimus in combination wtih erlotinib in patients with resistant solid tumors  
ConditionsSolid Tumors
InterventionDrug
Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future
TLDR
This review will highlight the role of Rapamycin and three rapamycin analogues in the treatment of sarcoma and the development of anticancer drugs that suppress protein synthesis and metabolism. Expand
Mechanisms of mTOR inhibitor resistance in cancer therapy
TLDR
The known mechanisms of resistance to mTOR-inhibitor therapy are summarized and potential strategies to overcome these for the current agents that target this pathway are described. Expand
Defining the role of mTOR in cancer.
TLDR
Recent progress in understanding mTOR signaling is discussed, paying particular attention to its relevance in cancer and the use of rapamycin in oncology. Expand
Mechanisms of resistance to mTOR inhibitors.
TLDR
Mechanisms of resistance to mTOR inhibitors are described, from preclinical and clinical perspectives, in breast cancer, renal cell carcinoma, neuroendocrine tumors and mantle cell lymphoma. Expand
Translational Control and mTOR in Cancer
TLDR
Among the broad spectrum of tumor entities that might be sensitive to mTOR targeting, glioblastoma (GBM) and colorectal cancer are chosen and the potential of mTOR pathway components as biomarkers as well as drug targets are reviewed. Expand
The biology behind mTOR inhibition in sarcoma.
TLDR
For the targeted treatment of sarcomas, AP23573 has shown promising clinical efficacy and low toxicity profiles in patients, and further studies should define the optimal dose/schedule, patient selection, and combination strategies with other biological agents, especially those targeting signaling pathways crucial for cell survival. Expand
mTOR signaling pathway and mTOR inhibitors in cancer therapy.
TLDR
Dual PI3K/mTOR kinase inhibitors have been developed with the idea of overcoming resistance to the mTOR inhibition through preventing the activation of PI3k/Akt as a result of release negative feedback loops. Expand
Mammalian target of rapamycin: biological function and target for novel anticancer agents.
  • E. Borders, Cory Bivona, P. Medina
  • Medicine
  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2010
TLDR
The mTOR signaling pathway is upregulated in a variety of solid and hematologic tumors and is a rational target for inhibition in combination with other agents, including traditional chemotherapy and agents that are affected by or target the PI3K pathway. Expand
Inhibitors of mTOR.
Inhibitors of mammalian target of rapamycin (mTOR) have been approved for the treatment of renal cell carcinoma and appear to have a role in the treatment of other malignancies. The primary objectiveExpand
The potential role of mTOR inhibitors in the treatment of endocrine tumors
TLDR
The main objective of this article is to summarize the available pre-clinical and clinical data regarding a possible role of mTOR inhibitors in the treatment of different endocrine cancers. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 209 REFERENCES
mTOR-targeted therapy of cancer with rapamycin derivatives.
TLDR
Evidence suggests that rapamycin derivatives could induce G1-S cell cycle delay and eventually apoptosis depending on inner cellular characteristics of tumour cells, and strategies aimed at detecting human tumours that express BCL-2 and other anti-apoptotic proteins might allow identification of rap Amycin-resistant tumours. Expand
An expanding role for mTOR in cancer.
TLDR
MTOR signaling is re-evaluate, suggesting a more central role for mTOR in cancers with defective PtdIns3K-PTEN signaling and conceptually discuss these implications in the context of drug discovery. Expand
IRS-1: auditing the effectiveness of mTOR inhibitors.
TLDR
In insight into the potential use of mTOR inhibitors, O'Reilly et al. provide evidence that poor tumor response to rapamycins is the result of relieving mTOR-mediated feedback inhibition of insulin receptor substrate 1, and activation of Akt-mediated survival. Expand
Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.
TLDR
The results indicate that the pharmacodynamic effects of CCI-779 can be determined using a p70(s6) kinase assay inPBMCs, suggesting that the PBMCs are an adequate surrogate tissue for p70-s6 kinase activity in vivo. Expand
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
TLDR
It is shown that loss of the Von Hippel-Lindau tumor suppressor gene (VHL) sensitizes kidney cancer cells to the mTOR inhibitor CCI-779 in vitro and in mouse models, providing preclinical rationale for prospective, biomarker-driven clinical studies of mTOR inhibitors in kidney cancer. Expand
Mammalian Target of Rapamycin (mTOR): Pro- and Anti-Apoptotic
TLDR
Cumulative evidence supports the hypothesis that mTOR acts as a master switch of cellular catabolism and anabolism, and has recently found to have profound effects on the control of apoptosis. Expand
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
TLDR
This study provides a mechanistic basis for enhancing mTOR-targeted cancer therapy by combining an mTOR inhibitor with a PI3K or Akt inhibitor and shows that rapamycin combined with LY294002 exhibited enhanced inhibitory effects on the growth and colony formation of cancer cells. Expand
Efficacy of a rapamycin analog (CCI‐779) and IFN‐γ in tuberous sclerosis mouse models
TLDR
Treatment with either an mTOR kinase inhibitor (CCI‐779, a rapamycin analog) or with IFN‐γ reduced the severity of TSC‐related disease without significant toxicity, and constitute definitive preclinical data that justify proceeding with clinical trials using these agents in selected patients with TSC and related disorders. Expand
Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma
Molecular markers enabling the prediction of sensitivity/resistance to rapamycin may facilitate further clinical development of rapamycin and its derivatives as anticancer agents. In this study,Expand
Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity
TLDR
It is found that MCF-7 breast cancer cell lines expressing a constitutively active Akt are able to proliferate under reduced estrogen conditions and are resistant to the growth inhibitory effects of tamoxifen, both in vitro as well as in vivo in xenograft models. Expand
...
1
2
3
4
5
...